WO2023090884A1 - Composition pharmaceutique comprenant un inhibiteur de prrx1 permettant la prévention ou le traitement du cancer - Google Patents

Composition pharmaceutique comprenant un inhibiteur de prrx1 permettant la prévention ou le traitement du cancer Download PDF

Info

Publication number
WO2023090884A1
WO2023090884A1 PCT/KR2022/018172 KR2022018172W WO2023090884A1 WO 2023090884 A1 WO2023090884 A1 WO 2023090884A1 KR 2022018172 W KR2022018172 W KR 2022018172W WO 2023090884 A1 WO2023090884 A1 WO 2023090884A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
prrx1
pharmaceutical composition
inhibitor
fibroblasts
Prior art date
Application number
PCT/KR2022/018172
Other languages
English (en)
Korean (ko)
Inventor
김석형
이근우
여소영
Original Assignee
사회복지법인 삼성생명공익재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사회복지법인 삼성생명공익재단 filed Critical 사회복지법인 삼성생명공익재단
Publication of WO2023090884A1 publication Critical patent/WO2023090884A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à une composition pharmaceutique permettant la prévention ou le traitement du cancer, la composition comprenant un inhibiteur de PRRX1 destiné à atténuer ou à inhiber l'expression ou l'activité de PRRX1 surexprimé dans les tissus cancéreux, en particulier dans les fibroblastes associés au cancer. Le fait de contenir un inhibiteur de PRRX1 en tant que principe actif permet à la composition pharmaceutique destinée à la prévention ou au traitement du cancer selon la présente invention d'inhiber la prolifération ou l'activité des tissus cancéreux, notamment des fibroblastes associés au cancer, et de faciliter la pénétration d'un agent thérapeutique anticancéreux dans les tissus cancéreux, résultant en la promotion apoptotique des tissus cancéreux, grâce à quoi la composition peut traiter efficacement divers cancers exprimant le PRRX1.
PCT/KR2022/018172 2021-11-17 2022-11-17 Composition pharmaceutique comprenant un inhibiteur de prrx1 permettant la prévention ou le traitement du cancer WO2023090884A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210158817A KR20230072259A (ko) 2021-11-17 2021-11-17 Prrx1 억제제를 포함하는 암 예방 또는 치료용 약학 조성물
KR10-2021-0158817 2021-11-17

Publications (1)

Publication Number Publication Date
WO2023090884A1 true WO2023090884A1 (fr) 2023-05-25

Family

ID=86397409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/018172 WO2023090884A1 (fr) 2021-11-17 2022-11-17 Composition pharmaceutique comprenant un inhibiteur de prrx1 permettant la prévention ou le traitement du cancer

Country Status (2)

Country Link
KR (1) KR20230072259A (fr)
WO (1) WO2023090884A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013134649A1 (fr) * 2012-03-09 2013-09-12 Verastem, Inc. Biomarqueurs pour des cellules souches cancéreuses et procédés d'utilisation associés
EP3461837A1 (fr) * 2017-09-28 2019-04-03 Secarna Pharmaceuticals GmbH & Co. KG Inhibiteur inhibant l'expression du pprx1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
KR20180125906A (ko) 2017-05-16 2018-11-26 아주대학교산학협력단 항암 치료 효과 증진용 약학 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013134649A1 (fr) * 2012-03-09 2013-09-12 Verastem, Inc. Biomarqueurs pour des cellules souches cancéreuses et procédés d'utilisation associés
EP3461837A1 (fr) * 2017-09-28 2019-04-03 Secarna Pharmaceuticals GmbH & Co. KG Inhibiteur inhibant l'expression du pprx1

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Nucleotide 26 October 2021 (2021-10-26), ANONYMOUS : "Homo sapiens paired related homeobox 1 (PRRX1), transcript variant pmx ", XP093068535, retrieved from NCBI Database accession no. NM_006902.5 *
JOKO RYOJI, YAMADA DAISUKE, NAKAMURA MASAHIRO, YOSHIDA AKI, TAKIHIRA SHOTA, TAKAO TOMOKA, LU MING, SATO KOHEI, ITO TATSUO, KUNISAD: "PRRX1 promotes malignant properties in human osteosarcoma", TRANSLATIONAL ONCOLOGY, NEOPLASIA PRESS, UNITED STATES, vol. 14, no. 1, 1 January 2021 (2021-01-01), United States , pages 100960, XP093068527, ISSN: 1936-5233, DOI: 10.1016/j.tranon.2020.100960 *
LEE KEUN-WOO, YEO SO-YOUNG, GONG JEONG-RYEOL, KOO OK-JAE, SOHN INSUK, LEE WOO YONG, KIM HEE CHEOL, YUN SEONG HYEON, CHO YONG BEOM,: "PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression", NATURE COMMUNICATIONS, vol. 13, no. 1, XP093068540, DOI: 10.1038/s41467-022-30484-4 *

Also Published As

Publication number Publication date
KR20230072259A (ko) 2023-05-24

Similar Documents

Publication Publication Date Title
Regan et al. Non-canonical hedgehog signaling is a positive regulator of the WNT pathway and is required for the survival of colon cancer stem cells
Cai et al. The Wnt–β-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion
Bitler et al. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence
KUMAR‐SINGH et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell‐type transition, and prognosis
Ng et al. Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa
CA2912389A1 (fr) Procedes et compositions pour reduire l'immunodepression par des cellules tumorales
Xu et al. NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2
Castiello et al. Disruption of IFN-I signaling promotes HER2/Neu tumor progression and breast cancer stem cells
WO2012005550A2 (fr) Composition pharmaceutique pour le traitement d'un carcinome de la vésicule biliaire et méthode d'inhibition de la croissance et des métastases d'un carcinome de la vésicule biliaire et le traitement d'un carcinome de la vésicule biliaire à l'aide de celle-ci
Hirukawa et al. Reduction of global H3K27me3 enhances HER2/ErbB2 targeted therapy
CN111073979B (zh) 阻断ccl28趋化通路的胃癌治疗方法
Mo et al. Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis
Feng et al. Genetic aberrations and interaction of NEK2 and TP53 accelerate aggressiveness of multiple myeloma
Chen et al. Melatonin attenuates hypoxia-induced epithelial-mesenchymal transition and cell aggressive via Smad7/CCL20 in glioma
Yang et al. Angiogenesis induced by signal transducer and activator of transcription 5A (STAT5A) is dependent on autocrine activity of proliferin
Li et al. MicroRNA-144-3p inhibits tumorigenesis of oral squamous cell carcinoma by downregulating ERO1L
WO2020080861A1 (fr) Composition de traitement du cancer gastrique comprenant un inhibiteur de syt11 en tant qu'ingrédient actif
Guo et al. DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs
An et al. The loss of epithelial Smad4 drives immune evasion via CXCL1 while displaying vulnerability to combinatorial immunotherapy in gastric cancer
WO2023090884A1 (fr) Composition pharmaceutique comprenant un inhibiteur de prrx1 permettant la prévention ou le traitement du cancer
WO2018004240A1 (fr) Utilisation de nupr1 dans le diagnostic et le traitement de la tumeur au cerveau
US20170298360A1 (en) Lats and breast cancer
WO2021137506A1 (fr) Composition pour inhiber la croissance de cellules souches cancéreuses, contenant un inhibiteur de wdr34 et utilisation correspondante
KR102612000B1 (ko) Glis1 발현 또는 활성 억제제를 포함하는 난소암 전이 억제용 약학적 조성물
CN111166769B (zh) 真皮成纤维细胞在治疗黑色素瘤中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22896086

Country of ref document: EP

Kind code of ref document: A1